AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 12 min read$LLY

Lilly's Foundayo Demonstrates Cardiovascular Safety In Landmark Diabetes Study

Eli Lilly (LLY) reported Phase 3 trial results showing Foundayo (orforglipron) met its primary cardiovascular safety objective in type 2 diabetes patients. The drug demonstrated a 16% lower risk of major adverse cardiovascular events compared to insulin glargine. LLY's stock closed at $1,157.08, down 2.33%, and was up 0.52% in overnight trading.

Original reporting
rttnews.com
Published Oct 1, 2026, 2:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 3:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The data could influence Lilly's upcoming guidance and affect valuation of the oral GLP‑1 franchise.

02

Market read

New cardiovascular safety data for a major diabetes drug may drive short‑term stock movement and longer‑term sector dynamics.

03

What to watch

Potential competition from injectable GLP‑1s and pricing pressures

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

The ACHIEVE-4 trial was presented at the EASD meeting and published in The Lancet, marking the first public disclosure of these results.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly disclosed Phase 3 ACHIEVE-4 trial results showing Foundayo's cardiovascular safety and A1C/weight benefits.

Expected impact

likely upward pressure as investors price in safety and efficacy data

Evidence & confidence

Phase 3 results are material for a large‑cap biotech; market typically reacts positively to safety wins.

Market effects

Sector

strengthens confidence in oral GLP‑1 class and may boost peers in diabetes/obesity space

Regional

U.S. biotech sector may see modest gains

Global

global diabetes market outlook improves with new safe oral therapy

Counterpoint

What could challenge this read

Some investors may question long‑term market adoption despite safety win

Key entities

  • company
    Eli Lilly and Company

    Pharmaceutical firm reporting trial results

  • drug
    Foundayo (orforglipron)

    Oral GLP‑1 therapy under study

Read at source← All news

Related articles

SEP 30
$LLYMedAI 8/10

Retatrutide Yields Significant Weight Loss in T2D

Eli Lilly's phase 3 TRIUMPH-2 study shows retatrutide, a triple hormonal agonist, achieved significant weight loss (up to 20.8%) and glycemic improvements in adults with type 2 diabetes (T2D) and obesity. The study, presented at EASD 2026, involved 1152 participants and showed retatrutide's efficacy estimand exceeded 20% weight reduction, a threshold not previously reached in T2D patients.

medscape.com3 min
SEP 30
$LLYHighAI 9/10

Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr

Eli Lilly (LLY) reported positive Phase 3 trial results for Foundayo, showing cardiovascular benefits in type 2 diabetes patients. The drug matched insulin glargine in preventing major adverse cardiovascular events while improving A1C levels and weight reduction. Foundayo reduced serious cardiovascular risks by 16%, cardiovascular mortality by 53%, and overall mortality by 57%.

gurufocus.com2 min
SEP 30
$LLYMedAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study | Eli Lilly and Company

Eli Lilly's oral GLP-1 drug, Foundayo (orforglipron), showed cardiovascular safety and sustained A1C reduction in the ACHIEVE-4 trial. Participants had a 16% lower risk of MACE-4 and 23% lower risk of MACE-3 vs. insulin glargine. Foundayo also demonstrated weight loss and improved cardiovascular risk factors. The trial involved 2,749 adults with type 2 diabetes and obesity or overweight.

investor.lilly.com3 min
SEP 30
$LLYHighAI 8/10

Weight-loss-drug makers unveil new data and deals

Eli Lilly presented Phase 3 data for retatrutide, showing 23% weight loss and significant blood sugar reductions. Novo Nordisk and Genentech licensed weight-loss molecules from Jiangsu Hengrui and Hanmi Pharmaceuticals, respectively, for upfront payments of $300M and $190M. Roche abandoned its obesity drug, emugrobart, after Phase 2 trial failures.

acs.org3 min
SEP 30
$LLYHighAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

Eli Lilly's Foundayo (orforglipron) showed a 16% lower risk of major cardiovascular events and 23% lower risk of cardiovascular death, heart attack, or stroke compared to insulin glargine in the ACHIEVE-4 trial. The drug also demonstrated improvements in A1C, weight, and other cardiometabolic health measures. Lilly plans to present these results at the EASD meeting and publish them in The Lancet.

prnewswire.com2 min